. Characterization of two melanin-concentrating hormone genes in zebrafish reveals evolutionary and physiological links with the mammalian MCH system.
The neonicotinoid insecticides have raised concerns regarding the health of bee pollinators. New research has identified a P450 enzyme that protects honey bees and bumble bees from the toxicity of two neonicotinoids, thiacloprid and acetamiprid. This P450 enzyme provides a margin of safety to bees.
Nicotine from tobacco was among the first chemical insecticides used to protect plants from sucking insects, some 200 years before the introduction of safer and more effective synthetic insecticides. Just as pyrethrins from Chrysanthemum flowers led to synthetic pyrethroids, nicotine inspired the design of what are now generically called the neonicotinoids. All of these compounds have nervous system targets. The neonicotinoids target the insect nicotinic acetylcholine receptors (nAchR) and, in contrast to nicotine itself, the neonicotinoids are much more toxic to insects than to vertebrates. Thus, nicotine is 600 times more potent towards vertebrate than fly nAchR, while the major neonicotinoid imidacloprid is 600 times less potent towards vertebrate than fly nAchR [1]. This considerable target-based selective toxicity explains the safety record of the neonicotinoids, which have gradually replaced the generally less selective organophosphorus and carbamate insecticides since their introduction on the market from 1991 to 2002 [2] .
Seven major neonicotinoid compounds make up about a quarter of the global insecticide market share [2] . Their remarkable success is due in part to their high water solubility. This allows translocation in plants as 'systemic' insecticides, thus targeting piercingsucking insects. The downside of this ability is that neonicotinoid residues can potentially find their way to nectar and pollen which are available to bee pollinators. Thus, in recent years the neonicotinoids have come under intense scrutiny for the risk they might pose to the health of managed and wild bee pollinators [3] .
Neonicotinoids Are Not All the Same Yet some neonicotinoids, specifically the cyanoamidines thiacloprid and acetamiprid, are generally considered safe to bees, with oral and contact toxicities 2-3 orders of magnitude lower than the nitroguanidine compounds such as imidacloprid, thiamethoxam and clothianidin. That such subtle changes in structure ( Figure 1 ) would translate to such dramatic changes in toxicity is quite remarkable by any standard of comparative toxicology. As reported in a recent issue of Current Biology, Manjon et al. [4] show that the nAchR of bees do not distinguish thiacloprid from imidacloprid so the target is equally sensitive to both types of neonicotinoids. Indirect evidence pointed to oxidative metabolism as the principal factor of this selective toxicity [5] . P450 enzymes are well recognized for their important role in xenobiotic metabolism, as for instance human CYP3A4, which is expressed in the liver and metabolises many drugs. Honey bees have comparatively fewer P450s than other insects, for example, less than a quarter of those found in mosquitoes [6, 7] . Manjon et al. achieved the goal of screening the in vitro activity of all 27 P450s from the CYP3 clan as recombinant enzymes. This Herculean effort identified four P450s capable of detoxifying thiacloprid and acetamiprid to less toxic metabolites. The most efficient one by far, CYP9Q3, was then transgenically expressed in Drosophila, resulting in a significant increase in the fly's tolerance to thiacloprid. This translated clear biochemical evidence to convincing physiological evidence. A close paralog of CYP9Q3 in the bumblebee Bombus terrestris was similarly identified as a thiacloprid and acetamiprid metaboliser. By contrast, these P450s metabolised imidacloprid only poorly.
Most neonicotinoids have similar application rates that lead to similar residue levels. Yet the 'sublethal' doses used in various biological assays purported to show negative effects of thiacloprid and acetamiprid on bees exceed by 2-3 orders of magnitude the typical residue levels found in honey or pollen [8, 9] . This is paradoxical because it would not be experimentally possible to conduct experiments at such high doses if not for the low toxicity of cyanoamidine neonicotinoids to bees. When documenting potential hazards, neonicotinoids are not all the same.
Toxicity to Bees and Bee Colony Health
What then does the selective toxicity advantage shown for cyanoamidine neonicotinoids at the individual level by Manjon et al. imply for bee colony health? Evaluating toxicity to honey bees or other social bees is more complex than evaluating toxicity to solitary bees, or non-social insects in general. Indeed, the end point is not survival of the individual, but the health of the colony, which is considered a superorganism of variable size, genotype and lifespan [10] . Thus, overall performance of the colony has been recommended by regulatory agencies as the criterion for risk assessment.
Foraging bees come into contact with potential toxicants when collecting pollen, nectar or resin (for propolis). But they are not the sole or primary consumers of the food they collect. The food is processed and shared by trophallaxis (food sharing). Foraging bees are therefore a 'first line of defense'. Significantly, CYP9Q3 gene expression is very high in the hind legs of foragers [11] , the ones used to collect and carry pollen in the corbiculae (pollen baskets) to the hive. Moreover, CYP9Q3 expression is induced by phytochemicals commonly found in pollen, honey and beebread such as p-coumaric acid and quercetin [12] . The mandibular glands and hypopharyngeal glands are also enriched in CYP9Q3 transcripts in foraging versus nurse bees [13] . It is therefore likely that acetamiprid or thiacloprid residues, if present, would rapidly be detoxified under natural conditions, thus explaining the absence of residues of these pesticides in bees [14] . As a second line of defense, CYP9Q3 expression is highest in the brain, particularly the mushroom bodies [4] involved in olfactory learning and memory.
The three CYP9Q enzymes of bees are P450s with relatively broad and somewhat overlapping specificity [4] . They also metabolise tau-fluvalinate and coumaphos, acaricides commonly used for in-hive control of the Varroa mite [15] . These P450s therefore play a key role in the defense of bees. They are, however, also prime potential targets for inhibitors, such as the DMI type of fungicides which are designed to inhibit fungal CYP51. Their co-occurrence with insecticides as residues in agricultural settings is documented. It is also known that they can inhibit non-fungal P450s at high concentrations in laboratory settings. High residue levels of DMI fungicides may therefore represent a risk factor, by making bees more sensitive to cyanoamidine neonicotinoids. However, under field conditions no effects of these fungicides on cyanoamidine neonicotinoid toxicity have been reported Thiacloprid is efficiently detoxified by the P450 enzyme CYP9Q3, but imidacloprid is only poorly metabolized. [6, 16] . It is unfortunate that the increase in market share of neonicotinoids has coincided with unrelated increases in negative factors such as the spread of the Varroa parasitic mite, diseases, and poor bee husbandry practices. The complexity of these multiple factors make neonicotinoids an easy target for blame. Yet neonicotinoids are commonly used in Australia, a continent still free of Varroa mites and of bee problems [17] . Access of bees to natural pollen rather than protein substitutes, or honey rather than sugar or corn syrup provides bees with phytochemicals ('nutraceuticals' [13] ) that induce detoxification enzymes and immune responses. This should be kept in mind when experimentally assessing bee health.
Five of the 57 human P450 enzymes are responsible for about 95% of drug metabolism reactions. Metabolism by the highly polymorphic CYP2C19 or CYP2D6 can lead to drug levels dangerously beyond the therapeutic range. Inhibition of CYP3A4 by one drug, or by foods such as grapefruit, can lead to abnormally high levels of another drug. These enzymes are therefore actively screened during development of new pharmaceuticals to avoid such potential adverse drug reactions. One may argue [6] , and the work of Manjon et al. [4] nicely shows, how the key detoxifying bee P450s could be also screened during the process of new insecticide design and discovery to afford selective toxicity and protect bee pollinators.
